Recent Posts
News•Feb 26, 2026
ARUP Creates Innovation Central Laboratory
ARUP Laboratories has unveiled the Innovation Central Laboratory, a dedicated hub for co‑development with pharmaceutical and biotech partners. The facility is designed to validate technologies and move next‑generation diagnostics from concept through to commercial readiness. It will host projects ranging from rare‑disease assay development to advanced genomic sequencing, AI‑driven digital pathology, and neurodegenerative biomarker discovery. By creating a collaborative ecosystem, ARUP aims to accelerate test adoption in clinical labs worldwide.
By CAP Today
News•Feb 24, 2026
Exa Capital Acquires Health Care Workforce Platform StaffReady
Exa Capital has acquired StaffReady, a SaaS platform that manages clinical workforces across hospitals, labs, and pharmaceutical testing firms. The platform streamlines staff scheduling, compliance, and inspection readiness, helping health‑care organizations reduce operational bottlenecks. StaffReady will remain independent with its...
By CAP Today
News•Feb 23, 2026
Copan’s PhenoMatrix Software Gets FDA 510(k) Clearance
Copan Group’s PhenoMatrix software, an AI‑driven image assessment tool for bacterial culture plates, received FDA 510(k) clearance as a Class II in‑vitro diagnostic device. The clearance covers analysis of blood, chocolate, MacConkey and ChroMagar agar plates, enabling semi‑quantitative colony counting and...
By CAP Today
News•Feb 20, 2026
Arlington Scientific Acquires ELISA Product Line
Arlington Scientific announced the completion of its acquisition of Awareness Technology’s EIA/ELISA product line on February 20, 2026. The deal adds a suite of ELISA kits and related reagents to Arlington’s existing immunoassay portfolio. By integrating the acquired assets, Arlington...
By CAP Today
Deals•Feb 20, 2026
Arlington Scientific Completes Acquisition of Awareness Technology's ELISA Product Line
Arlington Scientific announced the completion of its acquisition of the EIA/ELISA product line from Awareness Technology, expanding its portfolio in immunoassay technologies. Financial terms were not disclosed.
CAP Today
News•Feb 18, 2026
Hardy Dx Gets Breakthrough Designation for AMR Assays
The U.S. Food and Drug Administration has awarded breakthrough device designation to Hardy Dx’s NG-Test Candida auris and NG-Test Acineto‑5 assays. Both tests target antimicrobial‑resistant pathogens, promising faster, more accurate detection in clinical settings. The designation signals FDA’s confidence in the assays’ clinical...
By CAP Today
News•Feb 18, 2026
Digital Path Practices Reflected in Latest Checklist Changes
The College of American Pathologists issued the 2025 accreditation checklist on Dec. 9, adding a new “Digital Pathology Including Remote Data Assessment” section. The revision requires laboratories to validate digital pathology systems, document remote review locations, and treat remote CLIA‑certified sites...
By CAP Today
News•Feb 18, 2026
Lab Reins in Magnesium Tests with Decision Support
Washington University in St. Louis deployed a clinical decision‑support workflow to curb over‑ordering of inpatient magnesium tests, a high‑volume assay often ordered by default on daily order sets. Analysis of Epic data showed half of the orders were routine "AM...
By CAP Today
News•Feb 18, 2026
Pathologists, Vendors Talk LIS-IMS Integration
Pathology labs are accelerating digital transformation, but integrating laboratory information systems (LIS) with imaging management systems (IMS) remains a hurdle. Cybersecurity and image management top the agenda as AI-driven diagnostics expand. Cloud‑based LIS‑IMS solutions promise stronger security controls and scalable...
By CAP Today
News•Feb 17, 2026
Octave, Quest Expand Access to Octave MSDA Test
Octave Bioscience announced a collaboration with Quest Diagnostics to distribute its Octave Multiple Sclerosis Disease Activity (MSDA) test through Quest’s extensive specimen‑collection network. The test, a blood‑based biomarker panel, quantifies disease activity and helps clinicians tailor treatment for MS patients....
By CAP Today
News•Feb 17, 2026
Randox Type 1 Diabetes Risk Test Gets CE Mark
Randox Laboratories announced that its type 1 diabetes risk test has secured CE marking, authorising commercial launch across the European Economic Area. The assay detects genetic and immunological markers associated with heightened risk of developing type 1 diabetes, positioning it as a...
By CAP Today
News•Feb 17, 2026
CellaVision Bone Marrow Aspirate Application Gets CE Mark
CellaVision announced that its bone marrow aspirate application has received CE marking as a Class C in‑vitro diagnostic device under the EU IVD Regulation. The clearance confirms compliance with stringent safety and performance standards, allowing the software to be marketed throughout...
By CAP Today
News•Feb 17, 2026
BD Launches New FacsDiscover A8 Configurations
BD announced the launch of new FacsDiscover A8 cell analyzer configurations in February 2026. The updated offerings expand fluorescence detection capabilities, incorporate streamlined software workflows, and introduce modular hardware options for varied research needs. These configurations aim to improve data...
By CAP Today
News•Feb 17, 2026
Revvity Launches Somatic Cancer Reference Standards
Revvity announced the launch of highly characterized somatic cancer reference standards, created in partnership with the Medical Device Innovation Consortium (MDIC) and the National Institute of Standards and Technology (NIST). The standards are part of the Somatic Reference Samples Initiative...
By CAP Today
News•Feb 17, 2026
Natera Acquires Foresight Dx
Natera has completed the acquisition of cancer‑diagnostics firm Foresight Diagnostics, marking its most aggressive expansion into oncology. The deal adds a suite of liquid‑biopsy ctDNA tests to Natera’s portfolio, diversifying revenue beyond prenatal and hereditary screening. By integrating Foresight’s FDA‑cleared...
By CAP Today
News•Feb 17, 2026
Fujifilm and Voicebrook Partner
Fujifilm Healthcare Americas Corp. has announced a partnership with Voicebrook to embed the company’s VoiceOver Pro speech‑recognition platform into Fujifilm’s Synapse Pathology PACS. The integration allows pathologists to dictate reports and manage cases directly within the imaging system, aiming to...
By CAP Today
Deals•Feb 17, 2026
Natera Acquires Cancer Diagnostics Firm Foresight Diagnostics
Natera announced the completion of its acquisition of Foresight Diagnostics, a company specializing in cancer diagnostics. The deal expands Natera's oncology testing portfolio. Financial terms were not disclosed.
CAP Today